Showing results (171-180 of 186) with videos related to
Sort By:
Pageof 19
Science Translational Medicine|October 23, 2024
Cryptosporidium lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacyNicola Caldwell, Caroline Peet, Peter Miller, et al.Nature|July 27, 2018
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasisSusan Wyllie, Michael Thomas, Stephen Patterson, et al.Journal of Medicinal Chemistry|August 29, 2017
Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruziStephen Brand, Eun Jung Ko, Elisabet Viayna, et al.ACS Infectious Diseases|December 7, 2019
Setting Our Sights on Infectious DiseasesManu De Rycker, David Horn, Bree Aldridge, et al.Cell Chemical Biology|August 4, 2021
Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and preventionRobert L Summers, Charisse Flerida A Pasaje, Joao P Pisco, et al.Journal of Medicinal Chemistry|July 28, 2023
Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome InhibitorsMichael G Thomas, Kate McGonagle, Paul Rowland, et al.Nature Communications|October 11, 2022
Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugsSimon R Green, Susan H Davis, Sebastian Damerow, et al.Proceedings of the National Academy of Sciences of the United States of America|April 10, 2019
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibitionSusan Wyllie, Stephen Brand, Michael Thomas, et al.Nature Reviews. Chemistry|April 28, 2023
Towards the sustainable discovery and development of new antibioticsMarcus Miethke, Marco Pieroni, Tilmann Weber, et al.Nature Reviews. Chemistry|August 24, 2021
Towards the sustainable discovery and development of new antibioticsMarcus Miethke, Marco Pieroni, Tilmann Weber, et al.Pageof 19